Technical Analysis for ARQL - ArQule, Inc.

Grade Last Price % Change Price Change
grade C 3.74 -1.06% -0.04
ARQL closed down 1.06 percent on Friday, January 18, 2019, on 77 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical ARQL trend table...

Date Alert Name Type % Chg
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 Wide Bands Range Expansion -1.06%
Jan 17 Overbought Stochastic Strength -1.06%
Jan 16 Shooting Star Candlestick Bearish -2.09%
Jan 16 Pocket Pivot Bullish Swing Setup -2.09%
Jan 16 Wide Bands Range Expansion -2.09%
Jan 16 Overbought Stochastic Strength -2.09%
Jan 16 Up 3 Days in a Row Strength -2.09%
Jan 16 Upper Bollinger Band Touch Strength -2.09%

Older signals for ARQL ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
ArQule, Inc., a clinical-stage biotechnology company, engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. Its lead product candidate tivantinib is an inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase 3 clinical trial for the treatment of non-small cell lung and liver cancer; and Phase 2 clinical trial for the treatment of colorectal cancer. The company is also involved in the development of ARQ 087, an inhibitor of fibroblast growth factor receptor; ARQ 621, an inhibitor of the Eg5 kinesin motor protein; and ARQ 736, an inhibitor of the RAF kinases, which are in Phase 1 clinical development, as well as ARQ 761, an activator of the E2F-1 damage response/checkpoint pathway. It has partnership agreement with Daiichi Sankyo Co., Ltd. and Kyowa Hakko Kirin Co., Ltd. for implementing a clinical development program designed to realize the broad potential of tivantinib as a single agent; and in combination with other anti-cancer therapies in various disease indications. In addition, the company has research collaboration with Daiichi Sankyo Co., Ltd. to discover selective inhibitors of two kinases in the field of oncology based on its ArQule Kinase Inhibitor Platform (AKIP) technology. ArQule, Inc. was founded in 1993 and is headquartered in Woburn, Massachusetts.
Is ARQL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 7.21
52 Week Low 1.46
Average Volume 1,310,060
200-Day Moving Average 4.3921
50-Day Moving Average 3.419
20-Day Moving Average 3.121
10-Day Moving Average 3.54
Average True Range 0.3164
ADX 34.52
+DI 28.4976
-DI 11.9866
Chandelier Exit (Long, 3 ATRs ) 3.1858
Chandelier Exit (Short, 3 ATRs ) 3.1792
Upper Bollinger Band 4.0694
Lower Bollinger Band 2.1726
Percent B (%b) 0.83
BandWidth 60.775393
MACD Line 0.1136
MACD Signal Line 0.0012
MACD Histogram 0.1124
Fundamentals Value
Market Cap 266.19 Million
Num Shares 71.2 Million
EPS -0.38
Price-to-Earnings (P/E) Ratio -9.84
Price-to-Sales 29.83
Price-to-Book 7.11
PEG Ratio -0.47
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.10
Resistance 3 (R3) 4.10 3.98 4.04
Resistance 2 (R2) 3.98 3.89 3.98 4.02
Resistance 1 (R1) 3.86 3.83 3.80 3.86 4.00
Pivot Point 3.74 3.74 3.71 3.74 3.74
Support 1 (S1) 3.62 3.65 3.56 3.62 3.48
Support 2 (S2) 3.50 3.59 3.50 3.46
Support 3 (S3) 3.38 3.50 3.44
Support 4 (S4) 3.38